CALCIUM PHOSPHATE, UNSPECIFIED FORM

US Approved OTC

First marketed in 1921

Description
Sources: http://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479http://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttps://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.html
Curator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260884.htm | http://www.webmd.com/drugs/2/drug-159847/calcium-phosphate-dibasic-oral/details

Anhydrous dibasic calcium phosphate is a calcium salt of phosphoric acid. It is used as a diluent in pharmaceutical industry, in some toothpastes as a polishing agent. Calcium phosphate is generally recognized as safe by FDA. Dibasic calcium phosphate is ised as a supplement to treat conditions associated with calcium deficit, such as bone loss (osteoporosis), weak bones (osteomalacia/rickets), decreased activity of the parathyroid gland (hypoparathyroidism), and a certain muscle disease (latent tetany)

Originator

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2578
Hypocalcemia 75 Sources: http://www.globalrph.com/calcium_supplements.htm	Primary	Not Provided 504	Unknown Approved Use Unknown
Chronic obstructive pulmonary disease 174 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26265479	Palliative	Phase I 428	Unknown Approved Use Unknown
Cystic fibrosis 120 Sources: https://clinicaltrials.gov/ct2/show/NCT01543191	Palliative	Phase I 428	Unknown Approved Use Unknown
Unknown 2578
Hypocalcemia 75 Sources: https://www.drugs.com/mmx/calcium-phosphate-dibasic.html	Primary	Approved 8429	Unknown Approved Use Hypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred

PubMed

Title	Date	PubMed
Effects of terbutaline on force and intracellular calcium in slow-twitch skeletal muscle fibres of the rat.	1999 Apr	10372813
[Early stage of cardiomyopathy: mechanisms of damage and compensation].	1999 Jul	10643616
C-reactive protein in the hemolymph of Achatina fulica: interrelationship with sex steroids and metallothionein.	2000 Apr	10840224
Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist.	2000 Dec	11093801
Regulation of LPA-promoted myofibroblast contraction: role of Rho, myosin light chain kinase, and myosin light chain phosphatase.	2000 Feb 1	10640419
Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells.	2000 Jan 7	10617657
Effects of a calcimimetic compound and naturally activating mutations on the human Ca2+ receptor and on Ca2+ receptor/metabotropic glutamate chimeric receptors.	2000 Nov	11089548
Pharmacological blockade of ERG K(+) channels and Ca(2+) influx through store-operated channels exerts opposite effects on intracellular Ca(2+) oscillations in pituitary GH(3) cells.	2000 Nov	11040061
Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement.	2000 Oct 15	11054866
ATP induces dephosphorylation of myosin light chain in endothelial cells.	2000 Sep	10942722
Expression and functional analysis of chemokine receptors in human peripheral blood leukocyte populations.	2001 Apr 7	11298490
Molecular and functional characterization of a family of rat brain T-type calcium channels.	2001 Feb 9	11073957
Analysis of the native quaternary structure of vanilloid receptor 1.	2001 Jul 27	11358970
Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components.	2001 Jun	11356925
Long-term alteration of calcium homeostatic mechanisms in the pilocarpine model of temporal lobe epilepsy.	2001 Jun 8	11382382
Regional differences in functional receptor distribution and calcium mobilization in the intact human lens.	2001 Sep	11527950
The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells.	2002 Apr 19	11830588
Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells.	2002 Dec	12456425
Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones.	2002 Jul	12110441
Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor.	2002 Mar	11895442
Mechanism of enhanced calcium sensitivity and alpha 2-AR vasoreactivity in chronic NOS inhibition hypertension.	2003 Jan	12388232
[Prevention of osteoporosis by foods and dietary supplements. Bioavailability of milk micellar calcium phosphate].	2006 Oct	17012812
Effect of calcium phosphate and vitamin D₃ supplementation on bone remodelling and metabolism of calcium, phosphorus, magnesium and iron.	2014 Jan 17	24438153
Effects of ultrasound treatment on physico-chemical, functional properties and antioxidant activity of whey protein isolate in the presence of calcium lactate.	2018 Mar	28802019

Patents

Sample Use Guides

In Vivo Use Guide

oral: 500 to 2000 mg elemental calcium a day, in divided doses (bid-qid). inhalation: In a single-blind, phase 1B proof of concept study, 24 subjects were enrolled to sequentially receive three doses of PUR118 (calcium lactate inhalation powder (CLIP) formulation) (5.5 mg, n = 18; 11.0 mg, n = 18; 2.8 mg, n = 16). Each dose was inhaled 3 times (1, 13, 25 h, preceded by 2 puffs salbutamol) before the ozone exposure (250 ppb, 3 h intermittent exercise). Sputum was induced 3 h after the end of exposure.

Route of Administration: Other

In Vitro Use Guide

Unknown

Name

Type

Language

CALCIUM PHOSPHATE

Preferred Name

English

CALCIUM PHOSPHATE, UNSPECIFIED FORM

Common Name

English

CALCIUM PHOSPHATE [VANDF]

Common Name

English

CALCIUM PHOSPHATE [INCI]

Common Name

English

CALCIUM PHOSPHATE [II]

Common Name

English

CALCIUM PHOSPHATE [EP IMPURITY]

Common Name

English

CALCIUM PHOSPHATE [MART.]

Common Name

English

PHOSPHORIC ACID, CALCIUM SALT

Common Name

English

TRICALCII PHOSPHAS

Common Name

English

CALCIUM PHOSPHATE [EP MONOGRAPH]

Common Name

English

Classification Tree Code System Code

CFR

21 CFR 331.15